CENTRAL MEDICAL SERVICES SOCIETY

Ministry of Health & Family Welfare
(Autonomous Body under MoHFW, Govt. of India)
2nd Floor, Vishwa Yuvak Kendra, Pandit Uma Shankar Dikshit Road,
Chanakyapuri, New Delhi-110021 PHONE -:011-21410905/6, Fax -:011-21410849

Date: - 05/10/2023

Minutes of Pre-bid Meeting For Procurement of Inj. Artesunate, ACT AL Drugs & ACT SP Drugs FOR NCVBDC CPP Tender ID: 2023_CMSS_771547_1, dated 14/09/2023 Pre-bid Meeting held on 19/09/2023 at 12:00 PM

- 1. Following officials were present during the Pre-bid meeting: -
 - (i) Dr. C P Joshi, Joint Director (NCVBDC)
 - (ii) Mr. D Mohapatra, GM (Finance), CMSS
 - (iii) Ms. Anjana, GM (Procurement), CMSS
 - (iv) Mr. Lava Mishra, AGM (Procurement), CMSS
 - (v) Ms. Akanksha Jain, AGM (QA), CMSS
- 2. Following representatives from prospective bidders were present during the Pre-bid meeting: -

Sr. No.	Name of Representative	Name of Bidder
1.	Mr. R P Singh	M/s Health Biotech
2.	Mr. Arun Sharma	M/s Unicure India Ltd.
3.	Mr. Pawan Chopra	M/s Bharat Parenterals

3. Queries from following prospective firms were received via email: -

Sr. No.	Name of the bidders
1	M/s Unicure India Ltd.

4. Points raised by representatives of prospective bidders were discussed. After due consideration of the queries, the response/clarifications are enclosed.

<u>Annexure-1</u>
Pre-bid queries raised by the prospective bidders & response/clarifications by CMSS

Sr.	As per tender	Tender	Bidder's Representation	Bidder's	Response/
No.		Clause No.		Name	Clarifications
		& Page No.			
1.	Technical Specification	& Page No. Annexure- IA & Pg No. 41	This is with reference to the above-mentioned tender, we wish to inform you that, while going through the Technical specification of Tablet Artesunate we have observed that Tab Artesunate is required to be supplied in Indian pharmacopeia. Please note that Tab. Artesunate is not official in Indian Pharmacopoeia as on date. However, Artesunate API is official in Indian Pharmacopoeia. You are requested to kindly look into the same and issue an amendment for the same to enable us to participate in the tender. Copy of current Indian Pharmacopoeia for Artesunate API and our product permission is enclosed for your ready reference.	M/s Unicure India Ltd	Kindly refer the attached revised technical specifications of ACT-SP (Schedule VI to X).
			Also, please note that the tentative quantity mentioned in the tender is very small. Kindly inform the consignee wise distribution, as the transportation will be a major cost component while		
			quoting the rates.		

Note: - Above changes will be part of the tender document.

Sd/-GM (Procurement)

2	Description of Drug / product A)		Age-group wise colour code of Combi Blisters =>	Age groups	
	Each Combi Blister Pack: containing 3 tablet of Artesunate (each tablet of Artesunate 25mg strength) and 1 tablet of Sulphadoxine Pyremethamine (250mg + 12.5mg)	Total dose of Artesunate -75 mg divided over three days, Sulphadoxine Pyremethamine (250 mg + 12.5mg) single dose	PINK COLOR	Infant i.e. < 1year	Technical Specific
Jemes ?	Each Combi Blister Pack: containing 3 tablets of Artesunate (50 mg each) and 1 tablet of Sulphadoxine Pyremethamine (500mg+25mg)	Total dose of Artesunate – 150mg divided over three days, Sulphadoxine Pyremethamine – (500mg+25mg) single dose	YELLOW COLOR	1-4 Years	ation of Combi Bliste
	Each Combi Blister Pack containing 3 tablets of Artesunate (100mg each) and 1 tablet of Sulphadoxine Pyremethamine (750mg+ 37.5mg)	Total dose of Artesunate – 300mg divided over three days, Sulphadoxine Pyremethamine (750mg+37.5mg) single dose	GREEN COLOR	5-8 Years	Technical Specification of Combi Blister Packs of ACT-SP for different age group
Mullahr	Each Combi Blister Pack containing 3 tablets of Artesunate 150 mg and 2 tablets of Sulfadoxine Pyremethamine (500mg+ 25mg)	Total dose of Artesunate – 450mg divided over three days, Sulphadoxine Pyremethamine (1000mg+50mg) single dose	RED COLOR	9-14 Years	different age group un
1	Each Combi Blister Pack containing 3 tablets of Artesunate (each 200mg) and 2 tablets of Sulphadoxine Pyremethamine (750+37.5)mg each or 3 tablets of Sulphadoxine Pyremethamine (500mg+25mg) each	Total dose of Artesunate – 600mg divided over three days, Sulphadoxine Pyremethamine – (1500+75)mg single dose	WHITE COLOR	Adults	under NCVBDC
1		A Section			

The state of the s	CAUTION:				tablets :	B) Each Row - No. of			Nulled IV.
P	The blister strip should be superscribed that SP not to be given to children under 5 months.	One tablet of Artesunate (25mg)	Third Row (Day 3)	One tablet of Artesunate (25mg)	Second Row (Day 2)	ondi Pristmasto - d	Pyremethamine (250 mg +12.5 mg)	One tablet of Artesunate (25 mg) and one tablet of	First Row (Day 1)
James Shapes		One tablet of Artesunate (50mg)	Third Row (Day 3)	One tablet of Artesunate (50mg)	Second Row (Day 2)	Part Voterblyse vg	Pyremethamine (500+25mg)	One tablet of Artesunate (50 mg) and One tablet of	First Row (Day 1)
terrer.		One tablet of Artesunate (100mg)	Third Row (Day 3)	One tablet of Artesunate (100mg)	Second Row (Day 2)	Land Street of South	Sulphadoxine Pyremethamine (750mg+ 37.5)mg	One tablet of Artesunate (100mg) and one tablet of	First Row (Day 1)
		One tablet of Artesunate (150mg)	Third Row (Day 3)	One tablet of Artesunate (150mg)	Second Row (Day 2)	US VASSOUMS - IN	Sulphadoxine Pyremethamine (500+25mg)	One tablets of Artesunate (150 mg) and two tablets of	First Row (Day 1)
		One tablet of Artesunate (200mg)	Third Row (Day 3)	One tablet of Artesunate (200mg)	Second Row (Day 2)	Pyremethamine (500+25) mg each	Sulphadoxine pyremethamine (750+37.5) mg each or three tablets of Sulphadoxine	One tablet of Artesunate (200 mg) and two tablets of	First Row (Day 1)

E. Packing & Marking		Life/ Efficacy	D OF STATE O		C) Pharmacopoeial Requirement	
Marking: Printing/marking on Blister/Catch cover/corrugated box and pack will be as per Drug & Cosmetics Act 1940 and Rules made thereunder and as amended from time to time. Manufacturing and Expiry dates of Artesunate and Sulfadoxine - Pyremethamine tablets should be written separately on the Blister Pack/Catch Cover. Each Blister Strip will be stuffed in a paper catch cover. 25 Blister Strips will be placed in a pack and 100 such acks will be packed in a corrugated box. Each Blister Strip/Catch Cover/Pack and corrugated Box should be marked "NVBDCP, Dte.GHS SUPPLY- NOT FOR SALE" in contrasting colour.	All the packs in different groups will have definite colors as indicated above. The tablets will be placed in three rows with transparent top. Each row should be clearly marked as Day 1, Day 2 and Day 3 giving number of tablets in each row. Each pack should indicate dose schedule per kg body weight for both Tablet Artesunate and Tablet Sulphadoxine-Pyremethamine i.e. AS-4 mg/kg body weight and 25mg/ kg bw of sulphadoxine + 1.25 mg per kg bw of pyrimethamine respectively.	Each Pack will bear shelf life of minimum 2 years on the pack with manufacturing and expiry date. At least 5/6th of the minimum shelf life must remain at the time of delivery to the consignee. The supplier will provide manufacturer's stability test data substantiating the claimed shelf life in the offered package.	Tablet Artesunate: Minimum Two years Tablet Sulfadoxine + Pyremethamine: Minimum two years.	The product must be accompanied by in-house test reports of the batch supplied. (IP stands for Indian Pharmacopoeia)	Tablets Sulfadoxine Pyremethamine Combination: containing above strength (i.e Sulfadoxine I.P. 250mg and Pyremethamine I.P 12.5mg per tablet; Sulfadoxine I.P. 500 mg and Pyremethamine I.P 25mg per tablet and Sulfadoxine I.P. 750 mg and Pyremethamine I.P 37.5mg per tablet) as per IP latest version.	Tablets Artesunate 25mg, 50mg, 100mg, 150mg & 200mg containing Artesunate IP 25mg, 50mg, 100mg, 150mg & 200mg respectively.

G. Final Packing	F. Labelling
Supplies shall be securely packed in normal trade packing of corrugated boxes to avoid loss or damage during the transit by rail/road.	The label shall conform to the requirements of Drugs & Cosmetics Act 1940 and Rules made thereunder and as amended from time to time.

Technical Specifications approved as on 15th March 2023

Dr. Roop Kumari Representative-WHO-India

Sh. Manoj Kumar Sinha, Deputy Secretory (Procurement), MoHFW

Sh. Sanjeev Kumar DDC (I), CDSCO

Dr. Manik Shankaroo, Asst. Prof & HOD (Pharmacology), RML, Delhi

Dr. Rinku Sharma Jt. Dir (NCVBDC)

Dr. Tanu Jain Director (NCVBDC)

Director (Procurement), Dte.GHS, MoHFW

Dr. Manju Rahi Director-In-Charge, NIMR (ICMR)

Dr. Jatimder Katyal Prof. (Pharmacology), AllMS, Delhi

DDG (Store), MSO

Prof. (Dr.) Atul Goel, DGHS, Dte.GHS, MoHFW & Chairperson

Annexure-2

REVISED CRITICAL DATE SHEET ARE AS UNDER:

Description	Scheduled date
Bid Document Download End Date & time	12/10/2023 till 03:00 PM
Bid Submission End Date and Time	12/10/2023 till 03:00 PM
Last date of submission of original documents	13/10/2023 till 03:00 PM
Bid Opening Date and Time	13/10/2023 at 04:00 PM

Note: - Apart from above, all other terms & conditions of tender document will remain unchanged.

Sd/GM (Procurement)